🙌 ICYMI: @THilalMD, of the @MayoClinic, joined @chadinabhan on "The HemOnc Pulse" last week to talk about #MRD and whether he uses it to make treatment decisions in #CLL.
🎧 https://t.co/IEF5nG7xvv
@infonbpas, a physician-led organization providing another pathway for continuous board certification. Looking forward to see this supplant #ABIM and its extortion practices
Come to see our work (poster 1916), a meta-analysis about the association of MRD with PFS in CLL. Thanks @THilalMD for the opportunity to work on this after my last year observership @ASH_hematology#ASH23#CLLsm
Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy https://t.co/n5Y8GGq09r #ASH23
This episode of #HealthcareUnfiltered podcast the week of @ASH_hematology #ASH23 is W the inspiring @ARosenthalDO of @MayoClinic talking caring for AYA pts w cancer. Alison who survived cancer shares all.
Here’s the link & a clip:
https://t.co/dsN8uhfS3Q
@AaronGoodman33 I remember a time when the hospitalist used to say “I don’t agree with all these recs, let’s not order all these esoteric tests” but that seems to be a remnant of the past
New: Final results from the phase 3 HOVON/SAKK trial, comparing R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma
https://t.co/74MH7fEAn6